Investigational drug · Phase 3
AND017
Not approved by FDA. In 6 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Anemia Due to Chronic Kidney Disease, β -Thalassemia, Cancer-Related Anemia.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
6
6 still active
All registered trials
10
Any phase or sponsor naming "AND017"
First trial start
2024
May 27, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "AND017", any sponsor or status.
Conditions studied
As listed on its trial records.
- Anemia Due to Chronic Kidney Disease
- β -Thalassemia
- Cancer-Related Anemia
- Myelodysplastic Syndromes
- Chemotherapy Induced Anemia
Approved drugs for the same conditions: Myelodysplastic syndromes · Anemia · Chronic kidney disease · Oncology · Hematology and blood cancers · Rare and genetic disease · Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "AND017" as an intervention, largest first.
- A Study of AND017 to Evaluate Efficacy and Safety in Dialysis-Dependent Chronic Kidney Disease (DD-CKD) Patients With AnemiaPivotal-lookingActive, not recruiting
Kind Pharmaceuticals LLCIndustry
NCT07494409 · 300 participants (planned) · Start Oct 31, 2025 · Primary completion Feb 20, 2027
Drug: AND017 capsules; ESA · For: Anemia Due to Chronic Kidney Disease
Sites: Shanghai, China
- A Study of AND017 to Evaluate Efficacy and Safety in Patients With Anemia Due to Non-Dialysis-Dependent Chronic Kidney Disease (NDD-CKD)Pivotal-lookingRecruiting
Kind Pharmaceuticals LLCIndustry
NCT07487727 · 240 participants (planned) · Start Dec 3, 2025 · Primary completion Mar 1, 2027
Drug: AND017; ESA · For: Anemia Due to Chronic Kidney Disease
Sites: Beijing, China
- A Study of AND017 to Treat Anemia in Chronic Kidney Disease Patients on DialysisPivotal-lookingCompleted
Kind Pharmaceuticals LLCIndustry
NCT05265325 · 175 participants · Start May 3, 2023 · Primary completion Feb 29, 2024
Drug: AND017 capsules TIW; AND017 capsules QW and 1 more · For: Renal Anemia
Sites: Pine Bluff, Arkansas; Riverside, California; Lone Tree, Colorado · 25 sites in all
- A Study of AND017 to Treat Anemia in Non-dialysis-Dependent Chronic Kidney Disease (NDD-CKD) PatientsPivotal-lookingCompleted
Kind Pharmaceuticals LLCIndustry
NCT05035641 · 113 participants · Start Oct 18, 2021 · Primary completion Jul 5, 2023
Drug: AND017; Placebo · For: Renal Anemia
Sites: Northridge, California; Winter Park, Florida; Shreveport, Louisiana · 8 sites in all
Kind Pharmaceuticals LLCIndustry
NCT04751539 · 78 participants · Start Jul 16, 2018 · Primary completion Feb 11, 2019
Drug: AND017 single dose; AND017 multiple dose and 1 more · For: Healthy Volunteers
Sites: Randwick, Australia
Kind Pharmaceuticals LLCIndustry
NCT06302491 · 64 participants (planned) · Start May 27, 2024 · Primary completion Dec 2026
Drug: AND017 capsules; AND017 Placebo · For: β -Thalassemia
Sites: Guangzhou, China; Maoming, China; Liuzhou, China · 5 sites in all
Kind Pharmaceuticals LLCIndustry
NCT06304103 · 63 participants (planned) · Start Mar 14, 2025 · Primary completion Dec 2026
Drug: AND017 · For: Myelodysplastic Syndromes
Sites: Hangzhou, China
- A Study of AND017 to Treat Cancer Related Anemia in Patients Not Receiving ChemotherapyNot yet recruiting
Kind Pharmaceuticals LLCIndustry
NCT06075043 · 36 participants (planned) · Start Dec 2027 · Primary completion May 2028
Drug: AND017 · For: Cancer-Related Anemia
Kind Pharmaceuticals LLCIndustry
NCT06075030 · 36 participants (planned) · Start Dec 2027 · Primary completion Dec 2027
Drug: AND017 · For: Chemotherapy Induced Anemia
Kind Pharmaceuticals LLCIndustry
NCT04712500 · 14 participants · Start Jul 30, 2020 · Primary completion Aug 16, 2020
Drug: AND017 · For: Healthy Volunteers
Sites: Suzhou, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Anemia Due to Chronic Kidney Disease
- ESAErythropoiesis-Stimulating AgentPhase 33 trials
Kind Pharmaceuticals LLC · Anemia Due to Chronic Kidney Disease, Anemia of Chronic Kidney Disease
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.